ARDT INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Reminds Ardent Health (ARDT) Investors of Securities Class Action Deadline on March 9, 2026

Ardent Health (ARDT) discussed its Q2 2026 earnings call, citing operational cost reductions under its IMPACT program, including a 42% contract labor spend cut and 0.7% year-over-year SWB growth. It expects 2026 savings to rise to over $70 million and raised adjusted EBITDA outlook by $5 million to $10 million from a June payer renewal. Virtual care via hellocare.ai reported 58% discharge completion in Texas and Idaho.

Ardent Health, Inc. (ARDT) filed an SEC Form 8-K — Results of Operations and Financial Condition. 1 Exhibit 99.1 Ardent Health Reports Second Quarter 2026 Results Brentwood, Tenn. ( August 4, 2026 ) – Ardent Health, Inc. (NYSE: ARDT) ("Ardent Health" or the "Company"), a leading provider of healthcare in growing mid-sized urban communities across the U.S., today announced res

Moderna and Merck's experimental melanoma vaccine, combined with Keytruda, reduced recurrence or death risk by 42% in a Phase 3 trial. Despite positive results, Moderna's shares fell 18%, likely due to high investor expectations. The vaccine is personalized using mRNA technology, targeting unique tumor mutations. Trial data showed 82.2% of patients treated with the vaccine and Keytruda were alive without recurrence after two years, compared to 70% with Keytruda alone.

Vertex Pharmaceuticals reported positive Phase III results for povetacicept, showing a 52% reduction in proteinuria in kidney disease patients. The drug's safety profile was similar to placebo. Vertex also discussed inaxaplin's potential in treating APOL1-mediated kidney disease, with Phase III AMPLITUDE trial results expected early next year. The company is engaging with payers for povetacicept's commercial coverage.

Novartis' remibrutinib showed 31.2% to 35.2% lower annualized relapse rates vs. teriflunomide in two late-stage MS trials. Both trials met primary endpoints. Novartis plans global regulatory filings. Analysts estimate potential peak sales over $4B, though not company guidance.

Cumberland Pharmaceuticals (CPIX) reported Phase 2a trial results for ifetroban in systemic sclerosis, showing safety and tolerability but no efficacy conclusions. Shares fell 17.55% in after-hours trading. The 12-month trial enrolled 41 patients, with most experiencing limited disease progression. Cumberland plans further studies to guide future development.